AWM
WST icon

Abound Wealth Management’s West Pharmaceutical WST Stock Holding History

Abound Wealth Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$718 Sell
2
-11
-85% -$3.36K ﹤0.01% 883
2026
Q1 		$3.26K Hold
13
– – ﹤0.01% 815
2025
Q4 		$3.58K Hold
13
– – ﹤0.01% 750
2025
Q3 		$3.41K Hold
13
– – ﹤0.01% 724
2025
Q2 		$2.85K Buy
13
+5
+63% +$1.07K ﹤0.01% 692
2025
Q1 		$1.79K Sell
8
-4
-33% -$1.1K ﹤0.01% 714
2024
Q4 		$3.93K Buy
12
+3
+33% +$944 ﹤0.01% 576
2024
Q3 		$2.7K Hold
9
– – ﹤0.01% 666
2024
Q2 		$2.97K Sell
9
-10
-53% -$3.53K ﹤0.01% 596
2024
Q1 		$7.52K Buy
19
+7
+58% +$2.59K ﹤0.01% 433
2023
Q4 		$4.23K Hold
12
– – ﹤0.01% 550
2023
Q3 		$4.5K Sell
12
-1
-8% -$387 ﹤0.01% 489
2023
Q2 		$4.97K Buy
13
+2
+18% +$714 ﹤0.01% 484
2023
Q1 		$3.81K Hold
11
– – ﹤0.01% 473
2022
Q4 		$2.59K Buy
11
+8
+267% +$1.9K ﹤0.01% 497
2022
Q3 		$739 Buy
+3
New +$914 ﹤0.01% 632

Other funds holding WST

RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
SIM
Seilern Investment Management London, United Kingdom $794M AUM 6.63% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
GWI
Grace & White Inc Ny, New York $632M AUM 34.34% 1-Year Est. Return
MCG
McCollum Christoferson Group Amherst, New York $341M AUM 15.01% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
BZWA
Blue Zone Wealth Advisors Los Angeles, California $573M AUM 22.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Abound Wealth Management's WST Position: Q2 2026 in Review

Abound Wealth Management reduced its West Pharmaceutical (WST) stake by 85% in Q2 2026, selling an estimated $3.36K and leaving 2 shares worth $718. The position accounts for ﹤0.01% of the portfolio, ranked #883.

Abound Wealth Management first reported a position in WST in Q3 2022 and has held it in 16 quarters since. The position peaked at $7.52K in Q1 2024. 120 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Abound Wealth Management held 2 shares of West Pharmaceutical worth $718 as of Q2 2026.
  • Abound Wealth Management sold 11 West Pharmaceutical shares in Q2 2026, an estimated $3.36K.
  • West Pharmaceutical made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #883 holding.
  • Abound Wealth Management first reported a position in West Pharmaceutical in Q3 2022 and has held it in 16 quarters since.
  • Abound Wealth Management's West Pharmaceutical position peaked at $7.52K in Q1 2024.
  • 120 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.